Clinical Trial Update: Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating toripalimab plus anlotinib as maintenance therapy for extensive-stage small cell lung cancer; the study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Taizhou Hospital | Conditions: SCLC, Maintenance Treatment | Phase 3 | Status: NOT_YET_RECRUITING